

box / A

Address to: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

## UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of

Applicant (or identifier): BRAZZELL ET AL.

Title: METHOD OF TREATING OCULAR NEOVASCULARIZATION

Enclosed are:

1. ☒ Specification (Including Claims and Abstract) - 35 pages
2. ☐ Drawings - sheets
3. ☐ Executed Declaration and Power of Attorney (original or copy)
4. ☐ Microfiche Computer Program (appendix)
5. ☐ Nucleotide and/or Amino Acid Sequence Submission
  - ☒ Computer Readable Copy
  - ☒ Paper Copy
  - ☒ Statement Verifying Identity of Above Copies
6. ☐ Preliminary Amendment
7. ☐ Assignment Papers (Cover Sheet & Document(s))
8. ☐ English Translation of
9. ☐ Information Disclosure Statement
10. ☐ Certified Copy of Priority Document(s)
11. ☒ Return Receipt Postcard
12. ☒ Other: Unexecuted Declaration,  
Application Data Sheet

Filing fee calculation:

- ☐ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.  
☐ Before calculating the filing fee, please cancel claims \_\_\_\_\_.

Basic Filing Fee								\$	740
Multiple Dependent Claim Fee (\$ 280)								\$	
Foreign Language Surcharge (\$ 900)								\$	
	For	Number Filed		Number Extra		Rate			
Extra Claims	Total Claims	42	-20	22	x	\$	18	= \$ 396	
	Independent Claims	1	-3	0	x	\$	84	= \$	
TOTAL FILING FEE								\$	1,136


- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$1,136. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie  
Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,



David E. Wildman  
Attorney for Applicants  
Reg. No. 40,226  
Tel. No. (908) 522-6946

Date: February 21, 2002

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 913014714 US  
Express Mail Label Number

February 21, 2002  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BRAZZELL ET AL.

APPLICATION NO: Not Yet Assigned

FILED: February 21, 2002

FOR: METHOD OF TREATING OCULAR NEOVASCULARIZATION

Assistant Commissioner for Patents  
Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING  
INCLUDING STATEMENT OF VERIFICATION

Sir:

Applicants hereby provide a Computer Readable Form of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same.

Respectfully submitted,



David E. Wildman  
Attorney for Applicants  
Reg. No. 40,226

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6946  
Date: February 21, 2002

20020221.022102